Brief: Day One Reports Fourth Quarter And Full Year 2022 Financial Results And Corporate Progress

Day One Biopharmaceuticals

06/03/2023 23:36

March 6 (Reuters) - Day One Biopharmaceuticals Inc  DAWN.O :
    * DAY ONE REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL
RESULTS AND CORPORATE PROGRESS
    * DAY ONE BIOPHARMACEUTICALS INC - 2023NEW DRUG APPLICATION
SUBMISSION PLANNED FOR TOVORAFENIB (DAY101) IN FIRST HALF OF
2023
    * DAY ONE BIOPHARMACEUTICALS INC - CASH, CASH EQUIVALENTS
AND
SHORT-TERM INVESTMENTS TOTALED $342.3 MILLION ON DECEMBER 31,
2022
    * DAY ONE BIOPHARMACEUTICALS INC - NET LOSS TOTALED $40.1
MILLION
FOR Q4 OF 2022 COMPARED TO $21.9 MILLION FOR Q4 OF 2021

Source text for Eikon:  ID:nGNX9MxNS2 
Further company coverage:  DAWN.O